Today's cancer treatment methods often employ a "shotgun" approach because we lack the tools to determine the cancer's next move. Taking advantage of the fact that cancer cells can hijack the body's normal wound healing processes provides us with insight into cancer cell behavior. By studying how cancer cells utilize the inflammatory pathway triggered by our treatments, we can predict those patients who still harbor micrometastatic disease after treatment, and at the same time provide far more effective therapies for the treatment of cancer.
Encyt research has demonstrated that surgery, chemotherapy and radiation therapies trigger a distinct cytokine response that is expressed within a narrow window of time after treatment. Furthermore, our work has confirmed that a group of distinct cytokines foster rapid stem cell proliferation and EMT in tissue culture systems. In 2015, Encyt filed its first patent titled "Prevention of Metastasis and Recurrence after Primary Cancer Treatment".